[go: up one dir, main page]

GB201520949D0 - Inhibitors - Google Patents

Inhibitors

Info

Publication number
GB201520949D0
GB201520949D0 GBGB1520949.7A GB201520949A GB201520949D0 GB 201520949 D0 GB201520949 D0 GB 201520949D0 GB 201520949 A GB201520949 A GB 201520949A GB 201520949 D0 GB201520949 D0 GB 201520949D0
Authority
GB
United Kingdom
Prior art keywords
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1520949.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Ltd filed Critical Imperial Innovations Ltd
Priority to GBGB1520949.7A priority Critical patent/GB201520949D0/en
Publication of GB201520949D0 publication Critical patent/GB201520949D0/en
Priority to PCT/GB2016/053729 priority patent/WO2017089833A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G01N33/57515
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/44Multiple drug resistance
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GBGB1520949.7A 2015-11-27 2015-11-27 Inhibitors Ceased GB201520949D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1520949.7A GB201520949D0 (en) 2015-11-27 2015-11-27 Inhibitors
PCT/GB2016/053729 WO2017089833A1 (en) 2015-11-27 2016-11-28 Srebp transcription factor as biomarker for aromatase inhibitor resistance in oestrogen receptor a positive cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1520949.7A GB201520949D0 (en) 2015-11-27 2015-11-27 Inhibitors

Publications (1)

Publication Number Publication Date
GB201520949D0 true GB201520949D0 (en) 2016-01-13

Family

ID=55177331

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1520949.7A Ceased GB201520949D0 (en) 2015-11-27 2015-11-27 Inhibitors

Country Status (2)

Country Link
GB (1) GB201520949D0 (en)
WO (1) WO2017089833A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020077361A1 (en) * 2018-10-12 2020-04-16 The General Hospital Corporation Compounds and methods of their use
CA3253436A1 (en) * 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulation of immune responses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100120039A1 (en) * 2008-08-27 2010-05-13 Suzanne Fuqua Methods and compositions in breast cancer therapy resistance
WO2012097820A1 (en) * 2011-01-20 2012-07-26 Syddansk Universitet Method and assay for predicting long-term efficacy of tamoxifen treatment in estrogen receptor-positive breast cancer patients

Also Published As

Publication number Publication date
WO2017089833A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
IL287113A (en) Smyd inhibitors
IL260217B (en) Lsd1 inhibitors
IL255006A0 (en) Bromodomain inhibitors
IL246785A0 (en) Benzimidazol-2-amines as midh1 inhibitors
IL251784A0 (en) Bromodomain inhibitors
SG11201802665VA (en) Ferroportin inhibitors
IL248895A0 (en) Phosphatidylinositol -kinase inhibitors
ZA201907136B (en) Ip6k inhibitors
GB201513481D0 (en) Inhibitor compounds
IL256427A (en) Ido inhibitors
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
IL265139B (en) Dopamine-b-hydroxylase inhibitors
GB201612860D0 (en) Inhibitors
GB201505658D0 (en) Inhibitor compounds
IL253471A0 (en) Autotaxin inhibitors
ZA201800638B (en) Fucosidase inhibitors
GB201501004D0 (en) Inhibitors
IL274550A (en) Dopamine-b-hydroxylase inhibitors
AU361999S (en) Ballustrade
DK3133099T3 (en) Polymermodificeret polyoldispersion
IL253322A0 (en) Bace1 inhibitors
DK3242882T3 (en) Cgrp-antagonistpeptider
GB201520949D0 (en) Inhibitors
DK3250312T3 (en) Urea-metalnitrat-scr-system
GB201401005D0 (en) Inhibitor

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)